All Oncology News

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

Elraglusib plus chemotherapy generated early signals of antitumor activity in pediatric patients with relapsed/refractory Ewing and Ewing-related sarcomas.

RLY-2608 plus fulvestrant generated clinically meaningful PFS outcomes in PI3Kα-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

The TruSight Oncology Comprehensive Assay has been approved by the FDA with companion diagnostic claims in NSCLC and NTRK-positive solid tumors.

The study alters the existing paradigm that CDK1-Cyclin B1 is the only CDK-cyclin complex essential for all stages of mitosis.

R. Lor Randall, MD, FACS, highlights key findings from the pivotal MOTION trial of vimseltinib in patients with TGCT.

A CD44 and total protein level detecting oral rinse-based test showed promise in identifying disease recurrence for patients with head and neck cancer.

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

The NCCN Clinical Practice Guidelines in Oncology now list denileukin diftitox as an appropriate option for patients with cutaneous T-cell lymphoma.

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.